Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renvela in hyperphosphatemia (CKD non-dialysis)
NCT03001011Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2017
- Primary completion
- Aug 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperphosphatemia comparing Renvela Arm with Placebo Arm (2 arms). Primary endpoint: Change From Baseline in Serum Phosphorus at 8 weeks. Started Jun 2017; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT03001011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001011.